ClinicaliQ Trial Snapshot
- A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy — Active Not Recruiting • Phase III • NCT05337553.
- Trial testing a new add-on treatment (taldefgrobep alfa) alongside existing spinal muscular atrophy medicines to see if it helps and is safe.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This trial will study the efficacy and safety of taldefgrobep alfa as an adjunctive therapy for participants who are already taking a stable dose of nusinersen and/or risdiplam and/or have a history of onasemnogene abeparvovec, compared to placebo. Conditions: Spinal Muscular Atrophy, Neuromuscular Diseases, SMA Interventions: taldefgrobep alfa, Placebo, taldefgrobep alfa Lead Sponsor: Biohaven Pharmaceuticals, Inc. Planned Enrollment: 269 participants